“At the local level, companies looking to mitigate the increased costs are using a familiar set of strategies,” the 2023 Global Medical Trends Report from Aon says.
But the majority said their organizations were not prepared to take advantage of the currently existing data on such factors.
The FDA’s accelerated approval is usually based on a “surrogate marker” of effectiveness.
Sponsored by Edelman Financial Engines
Sponsored by Crossover Health
Sponsored by Progyny
- Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
- Exclusive discounts on BenefitsPRO.com and ALM events.
Copyright © 2022 ALM Global, LLC. All Rights Reserved.